22nd Century is a plant biotechnology company with an important mission: To Reduce the Harm Caused by Smoking.

Our long-term focus is the research, development, licensing, manufacturing, and worldwide sales and distribution of our important products. 22nd Century Group’s proprietary genetic engineering technology and plant breeding expertise allow us to regulate the level of nicotine (and other nicotinic alkaloids) in the tobacco plant. As a result of our unique technology, we are able to grow tobacco with up to 97% less nicotine than conventional tobacco – as well as plants with relatively high nicotine levels. The applications for this technology are extraordinary; in independent clinical studies, our Very Low Nicotine Content (VLNC) tobacco has demonstrated remarkable efficacy as a smoking cessation aid. On the other hand, for smokers who do not wish to quit, our high nicotine tobacco enables us to produce a cigarette with what we believe is the world’s lowest tar-to-nicotine ratio.

We believe that the tobacco industry is at the beginning of a paradigm shift toward the development and commercialization of reduced-risk tobacco products which represent a significant step toward achieving the public health objective of harm reduction. Our 18 years of research and development on the tobacco plant, mainly on the nicotine biosynthetic pathway, uniquely positions us to become a major benefactor of this paradigm shift developing in the tobacco industry. Our technology has created, and will continue to develop, a pipeline of products. We are primarily involved in the following activities:

  • The international licensing of 22nd Century Ltd’s technology, proprietary tobaccos, and trademarks

  • The research and development of potentially reduced-risk or modified risk tobacco products

  • The development of X-22, a prescription-based smoking cessation aid consisting of very low nicotine cigarettes

  • The manufacture, marketing and international distribution of RED SUN and MAGIC proprietary cigarettes

  • The production of SPECTRUM research cigarettes for the National Institute of Drug Abuse (NIDA)

  • The contract manufacturing of other companies’ branded tobacco products


22nd Century Group is organized around the following wholly-owned operating subsidiaries:

Goodrich Tobacco is focused on commercial tobacco products and potentially less harmful cigarettes.

Botanical Genetics is focused on natural, safe and effective cannabis/hemp-based products for human health, well-being and nutrition, in addition to industrial products refined from cannabis/hemp.

Heracles Pharmaceuticals is focused on X-22, a prescription smoking cessation aid in development.

NASCO Products is our manufacturing facility located in Mocksville, NC.